Affiliation:
1. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Abstract
Abstract
Curative therapy with an allogeneic hematopoietic cell transplant (HCT) can now be offered to a wider patient population due to improvements in donor selection, transplant conditioning regimens, and supportive care measures. However, risk of transplant-related morbidity and mortality remains, and thus appropriate transplant candidate workup pre-HCT for risk stratification and a management plan after HCT is crucial for success of the procedure. These include understanding and identifying risk of underlying malignant disease relapse, graft-versus-host disease, and infectious complications a patient may be predisposed toward, irrespective of allogeneic donor type. Progress in these domains with new therapeutic paradigms allows for development of a treatment plan prior to HCT to mitigate these potential risks tailored to the patient's case. Herein, we present case studies to focus on factors that influence decision-making in HCT and the approaches and strategies used to optimize post-HCT outcomes based on the individual HCT recipient's clinical scenario to improve on these high-risk scenarios.
Publisher
American Society of Hematology
Reference41 articles.
1. National Marrow Donor Program, a contractor for the C.W. Bill Young Cell Transplantation Program operated through the U. S. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau. Donor Registry. Last updated April 13, 2022. https://bloodstemcell.hrsa.gov/data/donation-and-transplantation-statistics. Accessed April1, 2023.
2. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides;Bolon YT,2022
3. From biology to clinical practice: aging and hematopoietic cell transplantation;Artz;Biol Blood Marrow Transplant,2012
4. Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT;Tsirigotis;Bone Marrow Transplant,2016
5. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis;Jimenez Jimenez;Bone Marrow Transplant,2021